Rift Valley Fever - PowerPoint PPT Presentation

About This Presentation
Title:

Rift Valley Fever

Description:

Department of Community Medicine & Primary Health Care ... Macular lesions. Retinitis. Retinal detachment. Death: rare. 2- Meningoencephalitis. Rate: 1.0 ... – PowerPoint PPT presentation

Number of Views:67
Avg rating:3.0/5.0
Slides: 35
Provided by: nah86
Learn more at: http://www.bibalex.org
Category:
Tags: fever | macular | rift | valley

less

Transcript and Presenter's Notes

Title: Rift Valley Fever


1
Rift Valley Fever
  • Sherine Shawky, MD, Dr.PH
  • Assistant Professor
  • Department of Community Medicine Primary Health
    Care
  • College of Medicine
  • King Abdulaziz University
  • shshawky_at_hotmail.com

2
Rift Valley Fever
  • Acute febrile viral disease
  • Affecting animals humans
  • Causes influenza-like illness
  • May lead to high morbidity, mortality economic
    loss

3
Geographic Location Geologic Feature of Rift
Valley
  • Length 6,000miles
  • Site Lebanon to Mozambique
  • Largest part Kenya
  • Development Subterranean forces
  • Feature Dambos

4
Causes of Outbreaks
Rainfall or Inundation
Wetlands Stagnant water
Vegetation Growth
Flourishing of mosquitoes
Transmission of Infection
5
Outbreaks in the Last Half Century
6
RVF Virus
Glyco- protein spikes
Lipid envelope
L
S
G1
M
G2
transcriptase
Coiled nucleocapsid RNAN protein
7
Mode of Transmission
  • Mosquitoes
  • Other blood suckling insects
  • Contact with blood or other body fluids of
    infected animals
  • Consumption of infected milk

8
Mode of Transmission(cont.)
  • Contact with blood or other body fluids of
    infected humans in late stages of disease
  • Airborne transmission
  • Inoculation through broken skin

9
Target
  • Liver focal necrosis
  • RBCs haemagglutination
  • Brain necrotic encephalitis

10
Clinical Picture 1- Non-Human Host
  • Fever
  • Hepatitis
  • Abortion
  • Death
  • Adults 10-30
  • Neonates 100

11
2- Human Host
  • Incubation period of 2-6 days
  • Asymptomatic
  • Flu-like illness
  • Abdominal pain
  • Photophobia
  • Recovery in 2-7days

12
Complications of RVF 1- Ocular Lesions
  • Rate 0.5-2.0
  • Onset 1-3 weeks
  • Presentation
  • Localized pain
  • Blurred vision
  • Loss of vision 1.0-10.0
  • Lesions
  • Macular lesions
  • Retinitis
  • Retinal detachment
  • Death rare

13
2- Meningoencephalitis
  • Rate lt 1.0
  • Onset 1-3 weeks
  • Death rare
  • Presentation
  • Severe headache
  • Vertigo
  • Seizures
  • Coma

14
3- Haemorrhagic fever
  • Lesions
  • Acute fulminant hepatitis
  • DIC
  • Hemolytic anemia
  • CFR 50.0
  • Rate lt 1.0
  • Onset 2-4 days
  • Presentation
  • hemorrhagic phenomenon

15
High Risk Groups
  • People who sleep outdoors at night
  • Slaughterhouse workers, butchers veterinarians
    and others who handle blood, other body fluids or
    tissues of infected animals

16
High Risk Groups (cont.)
  • Doctors and nurses in contact with infected cases
    at late stages of the disease
  • Laboratory technicians
  • Travellers visiting epidemic areas

17
Diagnosis of RVF
  • Antibody detection
  • ELISA
  • EIA
  • Virus detection
  • Virus isolation
  • Antigen detection
  • PCR

18
Prevention ControlI. Animal
  • Vaccination of unaffected animals
  • Live attenuated vaccine
  • Killed vaccine
  • Notification of affected animals
  • Application of safe insecticides to eradicate
    blood suckling insects

19
I- Animal(cont.)
  • Periodic surveillance of susceptible animals to
    assess immune status
  • Application of quarantine measures for testing of
    imported animals
  • Rapid burial of dead bodies

20
II- Vector
  • Removal of stagnant water
  • Weekly treatment of water collections using
    insecticides
  • Application of insecticides every other day in
    all gardens
  • Removal of objects that can act as possible water
    containers

21
III- Humans 1- General Measures
  • Sleeping indoors
  • Using bed nets during sleep
  • Putting screens on windows
  • Wearing clothes that protects whole body

22
III- Humans 1-General Measures (cont.)
  • Applying mosquito repellents
  • Using spray on clothes
  • Avoiding peaks of mosquito activity
  • Avoiding presence near vegetations in the evening

23
III- Humans1-General Measures (cont.)
  • Avoiding direct contact with animals
  • Washing hands after contact with animals, their
    blood or other body fluids
  • Avoid drinking raw milk

24
III- Humans 2- Community Measures
  • Health education
  • Epidemiologic research program
  • Active disease surveillance
  • Check measures at air, sea and land entry points

25
III- Humans3- Occupational Measures
  • Wearing masks, gloves, gowns and other barriers
    according to infected hosts condition
  • Laboratory samples should be handled by trained
    staff

26
III- Humans3- Occupational Measures (cont.)
  • Application of water, soap and antiseptic
    solution on exposed parts
  • Application of copious water and eye wash
    solution on exposed conjunctiva

27
Management of Suspected Cases
  • Notification
  • Ascertainment of cases
  • Identification, screening and surveillance of
    contacts

28
Recommended Investigations For Suspected Cases
  • CBC
  • Urea
  • Creatinine
  • AST, ALT
  • ALP,Bilirubin
  • Albumin
  • PT PTT
  • LDH CPK
  • Hepatitis A IgM IgG, HBsAg, HBcAB, HCV Ab
  • RFV seriology viral culture

29
Management of unhospitalised Patients
  • Isolation at home
  • Contacts should wear masks, gloves and protective
    clothes
  • Safe disposal of patients linens clothes
  • Close follow-up for 6 weeks

30
Indications For Hospitalisation
  • Thrombocytopenialt 100,000/mm3
  • Anaemialt 8gm/dL
  • Creatininegt150mol/L
  • Confusion or other CNS manifestation
  • Evidence of DIC
  • Shock
  • Decreased urine output
  • AST ALT gt 200U/mL
  • Bilirubingt100 mol/L

31
Management of Hospitalised Patients
  • General Supportive Measures
  • Isolation in negative airway pressure room
  • Safe disposal of soiled linens
  • Safe disposal of solid medical waste
  • Safe sewage disposal

32
Management of Hospitalised Patients (cont.)
  • Ribavirin, Interferon, Immune Modulators
    Convalescent Phase Plasma give promising results
  • Introduction to ICU or haemodialysis unit if
    indicated

33
  • Hospital discharge after
  • Improvement in general status
  • Decline in liver symptoms
  • Recovery from DIC
  • Follow-up in ophthalmology and medical clinics
    for 6 weeks
  • Safe burial practice for dead cases

34
Conclusion
  • RVF is spreading outside Africa
  • Although often mild, may lead to high morbidity
    and mortality
  • No vaccine for humans
  • No specific treatment
  • Preventive measures are crucial
Write a Comment
User Comments (0)
About PowerShow.com